Researchers from Cybin Inc. presented preclinical data for the potent and selective long-acting serotonin 5-HT2A receptor agonist, CYB-210010, as potential therapeutic candidate for the treatment of ...
SEATTLE--(BUSINESS WIRE)--Küleon LLC, a preclinical-stage biotechnology company building a best-in-class library of selective, G-protein-biased serotonergic medicines, today announced it has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback